<SEC-DOCUMENT>0001193125-23-266305.txt : 20231030
<SEC-HEADER>0001193125-23-266305.hdr.sgml : 20231030
<ACCEPTANCE-DATETIME>20231030172429
ACCESSION NUMBER:		0001193125-23-266305
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20231024
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231030
DATE AS OF CHANGE:		20231030

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MAIA Biotechnology, Inc.
		CENTRAL INDEX KEY:			0001878313
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41455
		FILM NUMBER:		231361577

	BUSINESS ADDRESS:	
		STREET 1:		444 WEST LAKE STREET, SUITE 1700
		CITY:			CHICAGO
		STATE:			IL
		ZIP:			60606
		BUSINESS PHONE:		312-416-8592

	MAIL ADDRESS:	
		STREET 1:		444 WEST LAKE STREET, SUITE 1700
		CITY:			CHICAGO
		STATE:			IL
		ZIP:			60606
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d570319d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:maia="http://www.maiabiotechnology.com/20231024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-10-24_to_2023-10-24">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-10-24_to_2023-10-24">0001878313</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="maia-20231024.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-10-24_to_2023-10-24"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-10-24</xbrli:startDate> <xbrli:endDate>2023-10-24</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-10-24_to_2023-10-24">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Current Report</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-10-24_to_2023-10-24" format="ixt:datemonthdayyearen">October&#160;24, 2023</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2023-10-24_to_2023-10-24">MAIA Biotechnology, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-10-24_to_2023-10-24" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-10-24_to_2023-10-24">001-41455</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-10-24_to_2023-10-24">83-1495913</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-10-24_to_2023-10-24">444 West Lake Street</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2023-10-24_to_2023-10-24">Suite 1700</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-10-24_to_2023-10-24">Chicago</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-10-24_to_2023-10-24">IL</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-10-24_to_2023-10-24">60606</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices with Zip Code)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-10-24_to_2023-10-24">(312)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-10-24_to_2023-10-24">416-8592</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-10-24_to_2023-10-24" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-10-24_to_2023-10-24" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-10-24_to_2023-10-24" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-10-24_to_2023-10-24" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-10-24_to_2023-10-24">Common Stock</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-10-24_to_2023-10-24">MAIA</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-10-24_to_2023-10-24" format="ixt-sec:exchnameen">NYSE American</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (17 CFR <span style="white-space:nowrap">&#167;240.12b-2).</span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-10-24_to_2023-10-24" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2023-10-24_to_2023-10-24" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;8.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;24, 2023, MAIA Biotechnology, Inc. (the &#8220;Company&#8221;) issued a press release announcing that it reported positive preliminary efficacy data from its ongoing Phase 2 clinical human trial, <span style="white-space:nowrap">THIO-101,</span> which evaluates THIO (our drug candidate that provides for an investigational dual mechanism of action that incorporates telomere targeting and immunogenicity) in patients with advanced <span style="white-space:nowrap">Non-Small</span> Cell Lung Cancer (&#8220;NSCLC&#8221;) in sequential combination with Regeneron&#8217;s <span style="white-space:nowrap"><span style="white-space:nowrap">anti-PD-1</span></span> cemiplimab (Libtayo<sup style="font-size:75%; vertical-align:top">&#174;</sup>), which is administered a few days after patients with advanced NSCLC are treated with THIO. The Company intends to continue providing updates on our <span style="white-space:nowrap">THIO-101</span> clinical trial as they become available. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October 30, 2023, the Company issued a press release announcing that an investigational new drug-enabling study of the Company&#8217;s second-generation telomere-targeting agents derived from lipid-modified THIO molecules generated positive results. The Company intends to continue to further study THIO conjugates as second generation cancer therapies. THIO&#8217;s telomere-centric action is currently being evaluated in Phase 2 of the THIO-101 clinical human trial, as described above. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of the press release, dated October 24, 2023, and the press release, dated October 30, 2023, are filed herewith as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Forward-looking Statements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company cautions that all statements, other than statements of historical facts, contained in this Current Report on Form <span style="white-space:nowrap">8-K,</span> or furnished herewith, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry&#8217;s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;future,&#8221; &#8220;potential,&#8221; or &#8220;continue,&#8221; and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement, including, but not limited to: (i)&#160;the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii)&#160;our ability to advance product candidates into, and successfully complete, clinical studies, (iii)&#160;the timing or likelihood of regulatory filings and approvals, (iv)&#160;our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v)&#160;the rate and degree of market acceptance of our product candidates, (vi)&#160;the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii)&#160;our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates. Any forward-looking statement speaks only as of the date on which it was made. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;9.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"><span style="font-weight:bold">Exhibit<br />No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d570319dex991.htm">Press release, dated October&#160;24, 2023 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d570319dex992.htm">Press Release, dated October 30, 2023. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL Document)</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: October&#160;30, 2023 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0">


<tr>

<td style="width:13%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:86%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">MAIA BIOTECHNOLOGY, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Vlad Vitoc</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Vlad Vitoc</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Executive Officer</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d570319dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MAIA Biotechnology Announces 100% Disease Control in Second-Line <FONT STYLE="white-space:nowrap">Non-Small</FONT> Cell Lung Cancer Demonstrating Impressive
Positive Preliminary Efficacy Data for Ongoing <FONT STYLE="white-space:nowrap">THIO-101</FONT> Phase 2 Trial </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Unprecedented disease control rate (DCR) of 100% in second-line of treatment far surpasses standard of care (SoC)
DCR of <FONT STYLE="white-space:nowrap">53-64%</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">DCR is far stronger than overall response rate (ORR) in predicting overall survival benefit, as shown in recent
meta-analysis of 74 clinical trials worldwide<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CHICAGO, IL &#150; October&nbsp;24,
2023 &#150; MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, today reported positive preliminary efficacy data from its ongoing Phase 2 clinical trial, <FONT
STYLE="white-space:nowrap">THIO-101,</FONT> evaluating THIO in patients with advanced <FONT STYLE="white-space:nowrap">Non-Small</FONT> Cell Lung Cancer (NSCLC) in sequential combination with Regeneron&#146;s <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> cemiplimab (Libtayo<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key findings: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">100% Preliminary DCR observed in second-line and 88% in third-line, in highly <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> patients who already progressed through previous lines of treatment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">DCRs across all dose levels met the <FONT STYLE="white-space:nowrap">pre-determined</FONT> statistical
requirements earlier than expected to proceed to next stage of the trial. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;In NSCLC patients who received at least one line of
therapy, DCRs have shown to be excellent predictors of overall survival.<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> Observing 100% DCR to date in second-line treatment is unprecedented compared to DCRs for the SoC ranging from <FONT
STYLE="white-space:nowrap">53-64%,</FONT><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&#148; said Vlad Vitoc, M.D., MAIA&#146;s Chief Executive Officer. &#147;We have also observed unprecedented high DCRs in third-line, with an 88% control
rate, with treatment of THIO followed by cemiplimab. The results are even more remarkable given patients in this population have previously failed treatment with a checkpoint inhibitor. Currently, there is no SoC for third-line, but previous studies
have reported an approximate 30% DCR.<SUP STYLE="font-size:75%; vertical-align:top">3</SUP> These exceptional preliminary results underscore our confidence in advancing the trial to bring our novel treatment to advanced stage NSCLC patients.&#148;
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Study Disease Control Rates by Line of Treatment </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Treatment Line</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Standard of Care Treatment</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>DCR</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Treatment&nbsp;Line</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>THIO +
Libtayo<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (cemiplimab) DCR</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">NSCLC-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">pembrolizumab <FONT STYLE="white-space:nowrap">(KEYNOTE-024)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">71%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">NSCLC-1</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">TBD</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle" ROWSPAN="2"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">NSCLC-2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ramucirumab + docetaxel (REVEL)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">64%</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2" ALIGN="center"><FONT STYLE="white-space:nowrap">NSCLC-2</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2" ALIGN="center">100%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">docetaxel monotherapy (REVEL)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">53%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">NSCLC-3</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">chemotherapy (RWD)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">25-35%</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">NSCLC-3</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">88%</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company presented the data at the European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on
October&nbsp;23, 2023. Full preliminary data is detailed in the poster available here. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About THIO </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIO <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(6-thio-dG</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">6-thio-2&#146;-deoxyguanosine)</FONT></FONT> is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> investigational telomere-targeting agent currently in clinical development to
evaluate its activity in <FONT STYLE="white-space:nowrap">Non-Small</FONT> Cell Lung Cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The
modified nucleotide <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">6-thio-2&#146;-deoxyguanosine</FONT></FONT> (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death.
THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive <FONT STYLE="white-space:nowrap">(T-cell)</FONT> immune </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Matsumoto H et al. Transl Lung Cancer Res. 2021 May; 10(5): 2278&#150;2289 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">REVEL https://www.cyramza.com/hcp/nsclc-treatment/revel-response-rate-efficacy </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Journal of Thoracic Oncology (VOLUME 16, ISSUE 10, OCTOBER 2021), T. Beninato et al. <SUP
STYLE="font-size:75%; vertical-align:top"></SUP> </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
responses. The sequential treatment with THIO followed by <FONT STYLE="white-space:nowrap">PD-(L)1</FONT> inhibitors resulted in profound and persistent tumor regression in advanced, in vivo
cancer models by induction of cancer type&#150;specific immune memory. THIO is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">standard-of-care</FONT></FONT> regimen of existing checkpoint inhibitors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
<FONT STYLE="white-space:nowrap">THIO-101,</FONT> Phase 2 Clinical Trial </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">THIO-101</FONT> is a multicenter,
open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate THIO&#146;s anti-tumor activity when followed by <FONT STYLE="white-space:nowrap">PD-(L)1</FONT> inhibition. The trial is testing the hypothesis that low
doses of THIO administered prior to Regeneron&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> cemiplimab (Libtayo<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>) will enhance and prolong
immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing a checkpoint inhibitor. The trial design has two primary objectives: (1)&nbsp;to
evaluate the safety and tolerability of THIO administered as an anticancer compound and a priming immune activator (2)&nbsp;to assess the clinical efficacy of THIO using Overall Response Rate (ORR) as the primary clinical endpoint. Treatment with
cemiplimab followed by THIO has been generally well-tolerated to date in a heavily <FONT STYLE="white-space:nowrap">pre-treated</FONT> population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier
NCT05208944. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About MAIA Biotechnology, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MAIA is
a targeted therapy, immuno-oncology company focused on the development and commercialization of potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> drugs with novel mechanisms of action that are
intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> cancer telomere targeting agent in
clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MAIA cautions that all
statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our
industry&#146;s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as &#147;may,&#148; &#147;might,&#148; &#147;will,&#148; &#147;should,&#148;
&#147;could,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;project,&#148; &#147;intend,&#148; &#147;future,&#148; &#147;potential,&#148; or &#147;continue,&#148; and other
similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i)&nbsp;the initiation, timing, cost,
progress and results of our preclinical and clinical studies and our research and development programs, (ii)&nbsp;our ability to advance product candidates into, and successfully complete, clinical studies, (iii)&nbsp;the timing or likelihood of
regulatory filings and approvals, (iv)&nbsp;our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v)&nbsp;the rate and degree of market acceptance of our product candidates,
(vi)&nbsp;the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii)&nbsp;our expectations regarding our ability to obtain and maintain intellectual property protection for our product
candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement
expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to
risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We
undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise,
&#147;MAIA,&#148; &#147;Company,&#148; &#147;we,&#148; &#147;our,&#148; and &#147;us&#148; refers to MAIA Biotechnology, Inc. and its subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Inquiries </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MAIA Biotechnology </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Joseph McGuire </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">jmcguire@maiabiotech.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">904-228-2603</FONT></FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Relations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ir@maiabiotech.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d570319dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MAIA Biotechnology Reveals Higher Anticancer Potency of Telomere-Targeting Compounds Derived from THIO </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Study results warrant further in vivo <FONT STYLE="white-space:nowrap">in-depth</FONT> investigation of THIO conjugates as second generation cancer
therapies. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CHICAGO, IL &#150; October&nbsp;30, 2023 &#150; MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing
telomere-targeting immunotherapies for cancer,<I> </I>today announced positive results from an investigational new drug-enabling study of the Company&#146;s second-generation telomere-targeting agents derived from lipid-modified THIO
molecules.&nbsp;MAIA&#146;s second-generation telomere-targeting molecule program seeks to discover new compounds with improved specificity towards cancer cells relative to normal cells, potentially increased anticancer activity, and stronger
chemistry manufacturing control characteristics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;In this study we demonstrated broad-spectrum therapeutically-attractive opportunities for specific
telomeric stress-inducing treatments. The results demonstrate an increase in innate sensing and adaptive antitumor immunity via the self-produced chemical modification of cancer cell telomeres by THIO,&#148; said MAIA&#146;s Chief Scientific Officer
Sergei Gryaznov, Ph.D. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The new THIO prodrugs are lipid conjugated compounds derived from THIO. The prodrugs are pharmacologically inactive compounds
that, after intake, are metabolized into a pharmacologically active drug.&nbsp;In vitro, these compounds were able to induce telomeric DNA damage responses that were similar or more profound than those for THIO, as assessed by quantitative Telomere
Damage Induced Foci assays (TIF formation). Efficient formation of micronuclei structures was also observed. Initial in vivo evaluation of the anticancer activity, conducted in human xenografts and murine syngeneic models of colorectal cancer,
demonstrated potent anticancer activity at relatively low dose levels for one of the lead lipid conjugates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Our findings from this study
demonstrate the significance of telomeric DNA structural and functional integrity for cancer cell survival. The high potency of these THIO-like agents warrants further in vivo <FONT STYLE="white-space:nowrap">in-depth</FONT> investigation as a
potential next generation of telomerase-mediated telomere-targeting compounds,&#148; said Vlad Vitoc, M.D., MAIA&#146;s Chief Executive Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
findings were presented by Dr.&nbsp;Gryaznov at the International Biochemistry Congress 2023, organized by the Turkish Biochemical Society and held in Turkey. The findings are detailed in the abstract available in the event website under Speakers,
Sergei M. Gryaznov and Lecture Abstract sections. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The telomere-centric action of MAIA&#146;s lead candidate THIO is being evaluated in Phase 2 clinical
trials <FONT STYLE="white-space:nowrap">(THIO-101)</FONT> in <FONT STYLE="white-space:nowrap">non-small-cell</FONT> lung carcinoma (NSCLC) patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About THIO </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIO <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">(6-thio-dG</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">6-thio-2&#146;-deoxyguanosine)</FONT></FONT> is a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> investigational telomere-targeting agent currently in clinical development to evaluate its activity in <FONT STYLE="white-space:nowrap">Non-Small</FONT>
Cell Lung Cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">6-thio-2&#146;-deoxyguanosine</FONT></FONT> (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic
micronuclei and activates both innate (cGAS/STING) and adaptive <FONT STYLE="white-space:nowrap">(T-cell)</FONT> immune responses. The sequential treatment with THIO followed by <FONT STYLE="white-space:nowrap">PD-(L)1</FONT> inhibitors resulted in
profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type&#150;specific immune memory. THIO is presently developed as a second or later line of treatment for NSCLC for patients that have progressed
beyond the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> regimen of existing checkpoint inhibitors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About MAIA Biotechnology, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MAIA is a targeted
therapy, immuno-oncology company focused on the development and commercialization of potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> drugs with novel mechanisms of action that are intended to
meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> cancer telomere targeting agent in clinical
development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking
statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry&#146;s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such
statements. The use of words such as &#147;may,&#148; &#147;might,&#148; &#147;will,&#148; &#147;should,&#148; &#147;could,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148;
&#147;project,&#148; &#147;intend,&#148; &#147;future,&#148; &#147;potential,&#148; or &#147;continue,&#148; and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that
statements are not forward-looking. For example, all statements we make regarding (i)&nbsp;the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii)&nbsp;our ability to
advance product candidates into, and successfully complete, clinical studies, (iii)&nbsp;the timing or likelihood of regulatory filings and approvals, (iv)&nbsp;our ability to develop, manufacture and commercialize our product candidates and to
improve the manufacturing process, (v)&nbsp;the rate and degree of market acceptance of our product candidates, (vi)&nbsp;the size and growth potential of the markets for our product candidates and our ability to serve those markets, and
(vii)&nbsp;our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by
our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such
forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed
in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future
events or otherwise, except as required by law. In this release, unless the context requires otherwise, &#147;MAIA,&#148; &#147;Company,&#148; &#147;we,&#148; &#147;our,&#148; and &#147;us&#148; refers to MAIA Biotechnology, Inc. and its
subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Inquiries </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MAIA Biotechnology
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Joseph McGuire </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">jmcguire@maiabiotech.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">904-228-2603</FONT></FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Relations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ir@maiabiotech.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>maia-20231024.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 10/31/2023 1:18:57 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:maia="http://www.maiabiotechnology.com/20231024"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.maiabiotechnology.com/20231024"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="maia-20231024_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="maia-20231024_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.maiabiotechnology.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>maia-20231024_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 10/31/2023 1:18:57 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>maia-20231024_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 10/31/2023 1:18:57 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.maiabiotechnology.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="maia-20231024.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140173117006320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 24, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001878313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 24,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MAIA Biotechnology, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-1495913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">444 West Lake Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Chicago<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">60606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(312)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">416-8592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MAIA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>d570319d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="maia-20231024.xsd" xlink:type="simple"/>
    <context id="duration_2023-10-24_to_2023-10-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <startDate>2023-10-24</startDate>
            <endDate>2023-10-24</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2023-10-24_to_2023-10-24">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-10-24_to_2023-10-24"
      id="Hidden_dei_EntityCentralIndexKey">0001878313</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-10-24_to_2023-10-24">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-10-24_to_2023-10-24">2023-10-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2023-10-24_to_2023-10-24">MAIA Biotechnology, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-10-24_to_2023-10-24">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-10-24_to_2023-10-24">001-41455</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-10-24_to_2023-10-24">83-1495913</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-10-24_to_2023-10-24">444 West Lake Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2023-10-24_to_2023-10-24">Suite 1700</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-10-24_to_2023-10-24">Chicago</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-10-24_to_2023-10-24">IL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-10-24_to_2023-10-24">60606</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-10-24_to_2023-10-24">(312)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-10-24_to_2023-10-24">416-8592</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-10-24_to_2023-10-24">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-10-24_to_2023-10-24">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-10-24_to_2023-10-24">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-10-24_to_2023-10-24">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-10-24_to_2023-10-24">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-10-24_to_2023-10-24">MAIA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-10-24_to_2023-10-24">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-10-24_to_2023-10-24">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2023-10-24_to_2023-10-24">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04
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MYHOA/UY_ 5!+ 0(4 Q0    (  Z+7E<'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ #HM>5[.M);'N
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ #HM>5YE<G",0!@  G"<  !,              ( !S $  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  .BUY7AWD8-VX$  "R$0
M&               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ #HM>5Y^@&_"Q @  X@P   T              ( !L0P  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    "  .BUY7EXJ[',     3 @  "P
M        @ &-#P  7W)E;',O+G)E;'-02P$"% ,4    "  .BUY7'#AEZC\!
M   \ @  #P              @ %V$   >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ #HM>5R0>FZ*M    ^ $  !H              ( !XA$  'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ #HM>5V60>9(9 0
MSP,  !,              ( !QQ(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2      D "0 ^ @  $10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d570319d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d570319d8k.htm">d570319d8k.htm</File>
    <File>maia-20231024.xsd</File>
    <File>maia-20231024_lab.xml</File>
    <File>maia-20231024_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d570319d8k.htm": {
   "nsprefix": "maia",
   "nsuri": "http://www.maiabiotechnology.com/20231024",
   "dts": {
    "inline": {
     "local": [
      "d570319d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "maia-20231024.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "maia-20231024_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "maia-20231024_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2022": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 24
   },
   "report": {
    "R1": {
     "role": "http://www.maiabiotechnology.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2023-10-24_to_2023-10-24",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d570319d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2023-10-24_to_2023-10-24",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d570319d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.maiabiotechnology.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.maiabiotechnology.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.maiabiotechnology.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.maiabiotechnology.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.maiabiotechnology.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.maiabiotechnology.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.maiabiotechnology.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.maiabiotechnology.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.maiabiotechnology.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.maiabiotechnology.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.maiabiotechnology.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.maiabiotechnology.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.maiabiotechnology.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.maiabiotechnology.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.maiabiotechnology.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.maiabiotechnology.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.maiabiotechnology.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.maiabiotechnology.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.maiabiotechnology.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.maiabiotechnology.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.maiabiotechnology.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentType",
     "presentation": [
      "http://www.maiabiotechnology.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.maiabiotechnology.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.maiabiotechnology.com//20231024/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193125-23-266305-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-266305-xbrl.zip
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MJ+?9]EOP\U;>BU&X]>9; ^#%OG@JXK51NI5?P,OD^JQ\R^7;U^M.A5<L_$6
M>^O_FT=/<97/#ZOPOUU2>S>JRNX-@_I( CYY1'W"QLQ-8C[$6!\4!\PZXO&
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M[GR<I<N(8](L  Q?K]'R!6X'QO 8S/D&M@C:MF^U[ZEZO._T&#ADK+7$N%4
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MXN6]31+?=GK]U(:))_=(/"Z.'+/*;C[PU&2 Z#1[ST3*L"=AE'!E5CW3$+T
M1.8]".&+8[:WNW6P?<3:[=>'MM>RW3Y\<U<OPT^=N.OH_\?3!DHAV2Q-8W.T
MLW-]?=WR%PF/OO*6KZ.=F1_O*..'OE<<+.\D&!^]W)UZV#+@%1VM/S7BB;T!
M/ZJ7^*?.$F4QQ&BF$^Y#<%NB_4^#B]\_]-C>JR;K7UW]#C_M-MF@,QJ<]X;D
M-;:;;-1BYT)AYZ_._0RQJ "3CV#2O:WGF"5U^Y_@LYLOHS,3Y&)L1;N:!6#B
M6V$27BK)?BP@MP'9A]=\89#=.S$N\G[(KOK_ P3O-_+W4A7DZ)<W]*?2-N#8
MV.E=CGK#'VX"[A1[V1P2LJT[I5;M2J_-K:Z?!]')QZZW=;&]MT3BKC_'N"87
MF\7%B9[H#&$/_(U%@EB4D!R$)<2FE$)B2U#1]R("ZET%6 N W $V0'K8Y3=>
M6'A(/41+Q)LN8F$CE8F%CY PATJ1@%46+=</;_+4-RRZ_K']!],4VU^&:1+B
MO(2M&3""[VQ7#?Y4-#>E,\B=73M3T>LZ%@MM\?=&LJY\FLG3$P^GF2K &9@(
M@B>&B!OL8H3(OJYQRGR_Q!FLX+&C@LWJK& G3\[N'!K<^)CF4\<:*;.%E !\
M&-EZLUX#55)>R,<B;-K&5-?8?\>$1XOUJ7T158027-?F%4"R-E6V@;%(1G'Y
MO$V09A^L\13YZ?4,I+\!VP6KLF["TH+D":M.2.9L$6-IT$BG]+!:O89;-477
M( \BV"26;' <)I'8C*>_>0;DWSX! IX1\D2A9I0\DP.#W!LR]GK-^9=BMNON
M61OK,[#_MM3O&$"NI73JGB>_LW1(I83=K9G[%3Y!WV0+(I56V-P)8'LG!R%@
MX>..]LFEA*VV@?L"D5XC@<"Y9,'T^$^;+YLCMK6W;6'+2GF$2@]\@B5"*C3H
M$#+UL0Q1&]<J SI91<J;I^ ZBHNXP&GI8MQ*Y*DTL&6K7:S/:+;3VDQA304:
MS9?-#+YGX+J2A[F ALOA.VY?D>]V^2H5$*]:I>9$E"5$H:5:E<V,UD/FC05P
MGI0<U@1[A*3=LSQQS>)Y&S-G,\'G\C$S&=BH3N)==JDO&VA;[#>=V+Y;J28X
M?V]#HNNTM3ZGW\^GR>*0FC'GTLBT\*_D7DUKJN>.9\@4;$)-L1"4U&N7G='N
M07OW\,W+E]^QY'KG7-]W" 2TMC3U&F>V?FAKY+8MWDX">CH'QOG\X$3[&1JG
MMA6Y<DD1=1MNBT3B Z_E5YX#%_"D#H8]<WTT2+*I\TBV:3@"MG(PRXB\-K=0
MBOPY  OP:Q#.5&"5-A(<_<@D0YV6$?BAN?5(X@9OHMV&Z"5H1T*#EMF5K(FW
MV"!+<-# N3 >841!F\%AS._&@1PCNJ(KJQ:&I0+[7E</SD<'5IKCJV,55+E=
M5BJ+$=!R+7:]L5:L$K/QB$MPHJ3YF)&W;E7ZGL/J@+9K;,&\T/H+<N4J!9=C
M"Y_?R^)\GB%''*X %UJOF8**)J,#23N L[R,P@!7!R&"!#<!339Y\,O/CQS@
MQX2$6-VDD86)W; 7N@TOWTF"NN,[>M1D%!G1.+XH'(U!:\B4_3F1Y@M0B[_9
M(T$J0$5<_=EN $G$[(@V&?$%;MO8]G]0#_@/K2_(3)HL"K#GIQD/\Z&!9C[L
M5,)^3<RI2*<0+M 7,PEW69KMY Y.-:"O)]PQF0BJ_],03#I#I$I16<84JR"J
MF<R?K3 %\0)1.L&Y\L#8.R#LV<D4V$K3C;FX"UB)7KV$0&KUBIGI+ R:^6""
MO>B7KKG[[,C5ZK4XY&KURG(+J]<!CB,W*J\$3!O=NA5\U)^W5K+N</7:)$NS
MI/IP[LWRRR")?$MP767%_84^@(X#Y EY@E-E+@FV6E;VP2X>+W*M9>NT]CT
MDCD-I(.D^-C0'(F=1 .Q69D%6AB"G.C5K0Y6E!N_K-B&]5SBAD?@JYHT=%=Z
MZ!I5ZPN"X"D\@T1MR1RL(910X J=JTL)W37!0$T*R5(.:8D;^4@,SI*!+>!
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M>9(LY6@P6*_7_>B.,LGC5:(D93_DBP%X7A$_GGR&/[)R(_A$8A)( HM )D3
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MR(SJ13)+/@8+:Z+-N9TN%2J,\.H8]X6"20]WG?!0 70)I%5"&WT;%@G6S6.
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M 5!+ 0(4 Q0    (  Z+7E=S,;:;$!0  --O   .              "  0
M  !D-3<P,S$Y9#AK+FAT;5!+ 0(4 Q0    (  Z+7E< EJXCF1,  /!3   1
M              "  3P4  !D-3<P,S$Y9&5X.3DQ+FAT;5!+ 0(4 Q0    (
M  Z+7E?D@O0-,PX  (HK   1              "  00H  !D-3<P,S$Y9&5X
M.3DR+FAT;5!+ 0(4 Q0    (  Z+7E=?6K9Z0@,  &@+   1
M  "  68V  !M86EA+3(P,C,Q,#(T+GAS9%!+ 0(4 Q0    (  Z+7E<+6K^5
MJP8  *5)   5              "  =<Y  !M86EA+3(P,C,Q,#(T7VQA8BYX
M;6Q02P$"% ,4    "  .BUY7Y'I!U.($   2+@  %0              @ &U
M0   ;6%I82TR,#(S,3 R-%]P<F4N>&UL4$L%!@     &  8 ?P$  ,I%
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
